Statistical and Practical Considerations for Clinical Evaluation of Predictive Biomarkers

Phase III Clinical Trials That Integrate Treatment and Biomarker Evaluation

(2013) Boris Freidlin et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials

(2012) Hai T Tran et al.   LANCET ONCOLOGY

The Influence of Low and Moderate Carotid Stenosis on Neurophysiologic Status of Patients Undergoing on-pump Coronary Artery Bypass Grafting

(2012) Olga Trubnikova et al.   Frontiers in Neurology

Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis

(2011) Claire L. Vale et al.   CANCER TREATMENT REVIEWS

Maintenance Therapy Comes of Age for Non–Small-Cell Lung Cancer, but at What Cost?

(2011) Frances A. Shepherd   JOURNAL OF CLINICAL ONCOLOGY

Prospective Molecular Marker Analyses ofEGFRandKRASFrom a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non–Small-Cell Lung Cancer

(2011) Wolfram Brugger et al.   JOURNAL OF CLINICAL ONCOLOGY

Biospecimen Reporting for Improved Study Quality (BRISQ)

(2011) Helen M. Moore et al.   JOURNAL OF PROTEOME RESEARCH

EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study

(2011) Robert Pirker et al.   LANCET ONCOLOGY

Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?

(2010) Michael Weller et al.   Future Oncology

Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non–Small-Cell Lung Cancer

(2010) Shirin Khambata-Ford et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Clinical Trials With Biomarkers: Design Issues

(2010) B. Freidlin et al.   JNCI-Journal of the National Cancer Institute

Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers

(2009) R. M. Simon et al.   JNCI-Journal of the National Cancer Institute

A Perspective on Challenges and Issues in Biomarker Development and Drug and Biomarker Codevelopment

(2009) S. E. Taube et al.   JNCI-Journal of the National Cancer Institute

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

(2009) Robert Pirker et al.   LANCET

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE